LKYMOTCinactive
Luckwel Pharmaceuticals Inc.
Healthcare·Immunology·Pre-clinical
ImmunologyCardiovascularInfectious DiseaseMetabolicMusculoskeletal
Luckwel Pharmaceuticals Inc. (LKYM): 15 pipeline candidates. Updated within the last hour.
7.3/10
BioSniper Score
3-factor signal · derived from public data
Cash RunwayN/A
N/A
Financial Health10.0
D/E -1.11 · 0% dilution
Pipeline Maturity2.0
Lead: Preclinical
Pipeline Breadth10.0
15 candidates
Catalyst MomentumN/A
N/A
Insider SignalN/A
N/A
A transparent, data-derived signal for Luckwel Pharmaceuticals Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$2K
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (15 candidates)
| Drug | Phase |
|---|---|
| cobeter 20/120 | — |
| cobeter 80/480 | — |
| kl-008 | Preclinical |
| kl-009 | Preclinical |
| kl-2118 | Preclinical |
| kl-2119 | Preclinical |
| kl-2120 | Preclinical |
| kl008 | Preclinical |
| kl009 | Preclinical |
| lucktor-10 | — |
Showing 10 of 15 candidates. Sign up for full pipeline.
Get the full picture on Luckwel Pharmaceuticals Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.